UBS Maintains Buy on Revolution Medicines, Raises Price Target to $265
Benzinga Newsdesk 2 months ago
NewsPrice TargetAnalyst Ratings
UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.
UBS analyst Michael Yee maintains Revolution Medicines (NASDAQ:RVMD) with a Buy and raises the price target from $220 to $265.